Background: Infantile epileptic spasms syndrome is an epileptic encephalopathy with poor prognosis. Objective: To describe clinical features and predictors of unfavorable outcomes of infantile epileptic spasms syndrome in a multiancestry cohort. Methods: Retrospective cross-sectional chart review analysis at a single tertiary pediatric hospital in 56 patients with infantile epileptic spasms syndrome. Results: Fifty-nine percent were males. Most patients (57%) were from the Middle East North African region. The mean age at onset of spasms was 6.6 months (±3.5 mo). At presentation, 80% of patients had a preexisting neurologic disorder, an abnormal development (66%), and/or an abnormal neurologic examination (73%). Hypsarrhythmia on electroencephalography (EEG) was reported in 55% of patients. Etiology was identified in 75%. Abnormalities on neuroimaging were common (70%), and 54% had abnormal genetic testing. The preferred first-line treatment was vigabatrin (66%) followed by high-dose oral steroids (16%). Only a minority (∼30%) experienced complete resolution of their epileptic spasms/hypsarrhythmia by 2 weeks. At the last follow-up, 84% of patients had an abnormal development and 40% were still on antiseizure medications. Comorbidities were common (75%). The majority of patients had unfavorable outcomes, including abnormal development (84%) and/or drug-resistant epilepsy (45%). Preexisting abnormal development/neurologic examination or neurologic conditions, perinatal risk factors, neuroimaging abnormalities, and an identified etiology were associated with increased odds ratios for unfavorable developmental outcomes or drug-resistant epilepsy. Significance: Clinical features and outcomes of infantile epileptic spasms syndrome in this multiancestry cohort confirms findings of previous epidemiologic studies, recognizes some differences, and highlights risk factors that can be used for early identification of patients with predicted unfavorable outcomes.
D’AlonzoRRiganteDMencaroniEEspositoS. West syndrome: a review and guide for paediatricians. Clin Drug Investig.2018;38:113-124. doi:https://doi.org/10.1007/s40261-017-0595-z
4.
WhelessJWGibsonPARosbeckKL,et al.Infantile spasms (West syndrome): update and resources for pediatricians and providers to share with parents. BMC Pediatr.2012;12:1-9. doi:https://doi.org/10.1186/1471-2431-12-108
5.
SahuJKMadaanPPrakashK. The landscape of infantile epileptic spasms syndrome in South Asia: peculiarities, challenges, and way forward. Lancet Reg Health Southeast Asia. 2023;12:100170. doi:https://doi.org/10.1016/j.lansea.2023.100170
ZuberiSMWirrellEYozawitzE, et al.ILAE Classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE task force on nosology and definitions. Epilepsia. 2022;63(6):1349-1397. doi:https://doi.org/10.1111/epi.17239
ChourasiaNYuskaitisCJLibensonMH,et al.Infantile spasms: assessing the diagnostic yield of an institutional guideline and the impact of etiology on long-term treatment response. Epilepsia. 2022;63(5):1164-1176. Epub 2022 Mar 18. PMID: 35211955. doi:https://doi.org/10.1111/epi.17209
12.
CarmantL. Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing. Acta Neurol Scand.2011;124:36-47. doi:https://doi.org/10.1111/j.1600-0404.2011.01599.x
SmithRJSugijotoARismanchiNHussainSAShreyDWLopourBA. Long-range temporal correlations reflect treatment response in the electroencephalogram of patients with infantile spasms. Brain Topogr.2017;30:810-821. doi:https://doi.org/10.1007/s10548-017-0588-5
Romero MilàBRemakanthakurup SindhuKMytingerJRShreyDWLopourBA. EEG biomarkers for the diagnosis and treatment of infantile spasms. Front Neurol.2022;13:960454. doi:https://doi.org/10.3389/fneur.2022.960454
HancockECOsborneJPEdwardsSW. Treatment of infantile spasms. Cochrane Database Syst Rev.2013;6:CD001770.
19.
FaulknerMATolmanJA. Safety and efficacy of vigabatrin for the treatment of infantile spasms. J Cent Nerv Syst Dis.2011;3:JCNSD.S6371. doi:https://doi.org/10.4137/JCNSD.S6371
20.
van der Poest ClementEJansenFEBraunKPPetersJM. Update on drug management of refractory epilepsy in tuberous sclerosis complex. Pediatr Drugs. 2020;22:73-84. doi:https://doi.org/10.1007/s40272-019-00376-0
21.
Suzuki-MuromotoSUematsuMSatoH, et al.Efficacy of vigabatrin therapy for tuberous sclerosis with infantile spasms. No Hattatsu Brain and Dev. 2016;48(6):413-419.
22.
FriedmanDBognerMParker-MenzerKDevinskyO. Vigabatrin for partial-onset seizure treatment in patients with tuberous sclerosis complex. Epilepsy Behav.2013;27(1):118-120. doi:https://doi.org/10.1016/j.yebeh.2012.12.033
23.
O'CallaghanF. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol. 2017;16(1):33-42.
24.
HahnJParkGKangHC,et al.Optimized treatment for infantile spasms: vigabatrin versus prednisolone versus combination therapy. J Clin Med.2019;8(10):1591. doi:https://doi.org/10.3390/jcm8101591
25.
BhallaSSkjeiK. Fulminant vigabatrin toxicity during combination therapy with adrenocorticotropic hormone for infantile spasms: three cases and review of the literature. Epilepsia. 2020;61(10):e159-e164. Epub 2020 Sep 17. PMID: 32944947. doi:https://doi.org/10.1111/epi.16663
26.
AramanadkaRSahuJKMadaanPSankhyanNMalhiPSinghiP. Epilepsy and neurodevelopmental outcomes in a cohort of West syndrome beyond two years of age. Indian J Pediatr. 2022;89(8):765-770.
27.
DjuricMKravljanacRTadicBMrlješ-PopovicNAppletonRE. Long-term outcome in children with infantile spasms treated with vigabatrin: a cohort of 180 patients. Epilepsia. 2014;55(12):1918-1925. doi:https://doi.org/10.1111/epi.12847
28.
WidjajaEGoCMcCoyBSneadOC. Neurodevelopmental outcome of infantile spasms: a systematic review and meta-analysis. Epilepsy Res.2015;109:155-162. doi:https://doi.org/10.1016/j.eplepsyres.2014.11.012
29.
YuskaitisCJRuzhnikovMRHowellKB, et al.Infantile spasms of unknown cause: predictors of outcome and genotype-phenotype correlation. Pediatr Neurol.2018;87:48-56. doi:https://doi.org/10.1016/j.pediatrneurol.2018.04.012
BittonJYDesnousBSauerweinHC, et al.Cognitive outcome in children with infantile spasms using a standardized treatment protocol. A five-year longitudinal study. Seizure. 2021;89:73-80. doi:https://doi.org/10.1016/j.seizure.2021.04.027
AlrifaiMTAlShayaMAAbulabanAAlfadhelM. Hereditary neurometabolic causes of infantile spasms in 80 children presenting to a tertiary care center. Pediatr Neurol.2014;51(3):390-397. doi:https://doi.org/10.1016/j.pediatrneurol.2014.05.015
34.
BashiriFAAl-SehemiMAHamadMH,et al.Neurodevelopmental and epilepsy outcomes of patients with infantile spasms treated in a tertiary care center. Neurosciences. 2021;26(1):21-25. doi:https://doi.org/10.17712/nsj.2021.1.20200087
35.
SalehDAHassanA. Clinical profile, treatment modalities, and outcomes in patients with infantile spasms: a retrospective study from the United Arab of Emirates (UAE). Epilepsy Behav.2022;127:108519. doi:https://doi.org/10.1016/j.yebeh.2021.108519
KurataniJPearlPLSullivanL, et al.American Clinical Neurophysiology Society guideline 5: minimum technical standards for pediatric electroencephalography. J Clin Neurophysiol.2016;33(4):320-323. doi:https://doi.org/10.1097/WNP.0000000000000321
39.
RazaliRMRodriguez-FloresJGhorbaniM, et al.Thousands of Qatari genomes inform human migration history and improve imputation of Arab haplotypes. Nat Commun. 2021;12:5929. https://doi.org/10.1038/s41467-021-25287-y
40.
DaidaAHamanoSIHayashiK, et al.Comparison of adrenocorticotropic hormone efficacy between aetiologies of infantile spasms. Seizure. 2021;85:6-11. doi:https://doi.org/10.1016/j.seizure.2020.12.008
41.
SuranaPSymondsJDSrivastavaP, et al.Infantile spasms: etiology, lead time and treatment response in a resource limited setting. Epilepsy Behav Rep. 2020;14:100397. doi:https://doi.org/10.1016/j.ebr.2020.100397
42.
WirrellECShellhaasRAJoshiCKeatorCKumarSMitchellWG. How should children with West syndrome be efficiently and accurately investigated? Results from the National Infantile Spasms Consortium. Epilepsia. 2015;56:617-625. doi:https://doi.org/10.1111/epi.12951
43.
HariniCShardaSBerginAM, et al.Detailed magnetic resonance imaging (MRI) analysis in infantile spasms. J Child Neurol.2018;33(6):405-412. doi:https://doi.org/10.1177/0883073818760424
44.
TrowbridgeSKYuskaitisCJBaumerNLibensonMPrabhuSPHariniC. Brain MRI abnormalities in patients with infantile spasms and Down syndrome. Epilepsy Behav.2019;92:57-60. doi:https://doi.org/10.1016/j.yebeh.2018.12.013
TappSAndersonTVisootsakJ. Neurodevelopmental outcomes in children with Down syndrome and infantile spasms. J Pediatr Neurol.2015;13(02):074-077. doi:https://doi.org/10.1055/s-0035-1556768
47.
KatsDJRocheKJSkotkoBG. Epileptic spasms in individuals with Down syndrome: a review of the current literature. Epilepsia Open. 2020;5(3):344-353. doi:https://doi.org/10.1002/epi4.12412
48.
NapuriSLe GallEDulacOChaperonJRiouF. Factors associated with treatment lag in infantile spasms. Dev Med Child Neurol.2010;52(12):1164-1166. doi:https://doi.org/10.1111/j.1469-8749.2010.03811.x
49.
EisermannMMDeLaRaillereADellatolasG,et al.Infantile spasms in Down syndrome—effects of delayed anticonvulsive treatment. Epilepsy Res.2003;55(1-2):21-27. doi:https://doi.org/10.1016/S0920-1211(03)00088-3
50.
RantalaHShieldsWDChristensonPD, et al.Risk factors of infantile spasms compared with other seizures in children under 2 years of age. Epilepsia. 1996;37(4):362-366. doi:https://doi.org/10.1111/j.1528-1157.1996.tb00572.x
51.
SumanasenaSPWanigasingheJArambepolaCSri RanganathanSMuhandiramE. Developmental profile at initial presentation in children with infantile spasms. Dev Med Child Neurol.2019;61(11):1295-1301. doi:https://doi.org/10.1111/dmcn.14205
52.
KnightEMManiJ. Historical overview of hypsarrhythmia and its association to epileptic spasms: a review of the medical literature from 1952 to 1982. J Clin Neurophysiol.2022;39(7):521-528. doi:https://doi.org/10.1097/WNP.0000000000000908
53.
HussainSAKwongGMillichapJJ, et al.Hypsarrhythmia assessment exhibits poor interrater reliability: a threat to clinical trial validity. Epilepsia. 2015;56(1):77-81. Epub 2014 Nov 10. PMID: 25385396. doi:https://doi.org/10.1111/epi.12861
54.
GailyELiukkonenEPaetauRRekolaRGranströmML. Infantile spasms: diagnosis and assessment of treatment response by video-EEG. Dev Med Child Neurol. 2001;43(10):658-667. PMID: 11665822. doi:https://doi.org/10.1017/s0012162201001207
55.
GrinspanZMKnuppKGPatelAD, et al.Comparative effectiveness of initial treatment for infantile spasms in a contemporary US cohort. Neurology. 2021;97(12):e1217-e1228. PMID: 34266919; PMCID: PMC8480478. doi:https://doi.org/10.1212/WNL.0000000000012511
56.
GuangSMaoLZhongL,et al.Hormonal therapy for infantile spasms: a systematic review and meta-analysis. Front Neurol. 2022;13:772333. PMID: 35222241; PMCID: PMC8867209. doi:https://doi.org/10.3389/fneur.2022.772333
57.
Sánchez FernándezIAmengual-GualMBarcia AguilarC, et al.Temporal trends in the cost and use of first-line treatments for infantile epileptic spasms syndrome. Epilepsia. 2023;64(3):630-640. Epub 2023 Jan 31. PMID: 36600453. doi:https://doi.org/10.1111/epi.17498
58.
DanielsDKnuppKBenkeTWolter-WarmerdamKMoranMHickeyF. Infantile spasms in children with Down syndrome: identification and treatment response. Glob Pediatr Health. 2019;6:2333794X18821939. doi:https://doi.org/10.1177/2333794X18821939
59.
LuxALEdwardsSWHancockE, et al.The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet.2004;364(9447):1773-1778. doi:https://doi.org/10.1016/S0140-6736(04)17400-X
60.
NelsonJADemarestSThomasJJuarez-ColungaEKnuppKG. Evolution of infantile spasms to Lennox-Gastaut syndrome: what is there to know?J Child Neurol.2021;36(9):752-759. doi:https://doi.org/10.1177/08830738211000514
61.
BebinEMPetersJMPorterBE, et al.Early treatment with vigabatrin does not decrease focal seizures or improve cognition in tuberous sclerosis complex: the PREVeNT trial. Ann Neurol. 2024;95(1):15-26. Epub ahead of print. PMID: 37638552; PMCID: PMC10899525. doi:https://doi.org/10.1002/ana.26778
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
